Tumor tissue or cells obtained from biopsy, surgical resection or centrifugated pleural effusion deposit were tested for gene alterations using next‐generation sequencing (NGS) or polymerase chain reaction (PCR) methods by the department of pathology of our center or by third‐party genetic testing companies that had accredited qualifications from College of American Pathologists (CAP). PD‐L1 immunohistochemistry was performed on the tumor samples from the same tissue origin with the Dako 22C3 pharmDx test kit. The PD‐L1 tumor proportion score (TPS) was calculated as the number of viable tumor cells presenting complete or partial membrane staining divided by the total number of all tumor cells multiplied by 100.
22c3 pharmdx test kit
Manufactured by Agilent Technologies
The 22C3 pharmDx test kit is a qualitative immunohistochemistry assay designed for the detection of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and urothelial carcinoma tissue specimens. The test kit provides information on the expression level of PD-L1 in the tested tissue samples.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using 22c3 pharmdx test kit
1
Molecular Profiling of Tumor Samples
2
Lung Adenocarcinoma: PD-L1 Low, Immunotherapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This retrospective study enrolled 205 patients from 4 cancer centers (Shandong Cancer Hospital and Institute, QiLu Hospital of Shandong University, Shandong Provincial Hospital, and Affiliated Hospital of Qingdao University) from January 1, 2018, to June 30, 2022. The inclusion criteria were as follows: (1) lung adenocarcinoma confirmed by cytology or histology; (2) stage IV disease according to the American Joint Committee on Cancer Staging manual v8; (3) PD-L1 expression < 1%, as assessed using the Dako 22 C3 pharmDx test kit, and (4) receiving IBC, BC, or IC as first-line therapy. Patients harboring EGFR mutations and ALK/ROS-1 rearrangements were excluded. The last follow-up appointment was on July 19, 2023.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!